-
Innovation Ranking
NewInnovation Ranking – Biocon Ltd
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It...
-
Company Insights
Innovation and Patenting activity of Biocon Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Biocon Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Adalimumab Biosimilar in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adalimumab Biosimilar in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adalimumab Biosimilar in Rheumatoid Arthritis Drug Details: Adalimumab biosimilar is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Adalimumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adalimumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adalimumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details:...
-
Thematic Analysis
Biosimilars in Oncology – Thematic Intelligence
Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you: Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain. Assess the marketed and pipeline products and their uptake across 8MM. Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products. Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars....
-
Product Insights
Febrile Neutropenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Febrile Neutropenia - Drugs In Development, 2023’, provides an overview of the Febrile Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Febrile Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Optic Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Optic Neuropathy - Drugs In Development, 2023’, provides an overview of the Optic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lupus Nephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Lupus Nephritis - Drugs In Development, 2023’, provides an overview of the Lupus Nephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...